Back to Results

Purple Biotech (PPBT)

Purple Biotech Ltd. is an ADR representing common stock of the company and trades on NASDAQ under the ticker PPBT. The underlying issuer is a clinical-stage healthcare company focused on developing cancer therapies aimed at addressing tumor immune evasion and drug resistance. Its oncology pipeline includes CM24, a humanized monoclonal antibody being studied in Phase 2 for pancreatic ductal adenocarcinoma in combination with anti-PD-1 checkpoint inhibitors, and NT219, a small molecule in Phase 2 trials for recurrent and/or metastatic head and neck squamous cell carcinoma and colorectal adenocarcinoma. The company is also advancing CAPTN-3, including IM1240 and IM1305, a multi-valent antibody program in preclinical development. Purple Biotech has a collaboration with Bristol Myers Squibb to evaluate CM24 with nivolumab and chemotherapy. Formerly known as Kitov Pharma Ltd., the company adopted its current name in December 2020 and is headquartered in Rehovot, Israel.


Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Technical Outlook FAQ

Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.

Data update note: Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
Ticker Fair Value Fair Value Upside/Downside Fair Value Rating Analyst Price Target Analyst Target Upside/Downside Analyst Target Rating Overall Financial Health Upcoming Dividend Ex-Date Dividend Payment Date Upcoming Dividend Dividend Yield Next Earnings Date P/E Ratio Price-to-Book Ratio Price-to-Sales Ratio Market Cap Enterprise Value Total Debt / Total Capital Free Float / Shares Outstanding Altman Z-Score Payout Ratio Free Cash Flow / Net Income
NASDAQ-PPBT
—
—
—
$30 2,073.9% Upside
—
Bargain
Fair
—
—
—
0.0%
July 30, 2026
-0.2x
0.6x
—
6.118 M
-408.685 K
3.0%
99.4%
-79.1
—
26.1%
Valuation • Fair Value

Purple Biotech (NASDAQ-PPBT) Fair Value by Valuation Model

Compare the primary fair value estimate for Purple Biotech (NASDAQ-PPBT) with model-based valuation references such as DCF, Ben Graham, DDM, EPV and comparable-company valuation.

Primary Valuation Read

Fair Value

Not available

Data is currently unavailable.

Fair Value Confidence

Low

Confidence level for the primary fair value estimate.

DCF Fair Value

NM

Discounted cash flow valuation reference.

Ben Graham Formula Value

$0

Classic Ben Graham valuation formula reference.

DDM Fair Value

NM

Dividend discount model valuation reference.

EPV Fair Value

NM

Earnings power value estimate.

Comps Fair Value

NM

Comparable-company valuation reference.

Analyst Price Target

$30 2,073.9% Upside

Current consensus analyst target, where available.

How to read these valuation models

Use this section to compare the primary fair value estimate for Purple Biotech (NASDAQ-PPBT) with several model-based valuation references. Different models can produce different outputs because each method relies on a different set of assumptions, so the primary fair value estimate should be read alongside the model spread rather than in isolation.

Profitability • Growth

Profitability & Growth for Purple Biotech (NASDAQ-PPBT)

A compact read on revenue, forward revenue expectations, EBITDA and operating profitability trends.

Revenue

Not available

Data is currently unavailable.

Revenue Forecast

0 K

Forward revenue estimate.

EBITDA

-7.798 M

Current operating profitability reference.

EBITDA Forecast

Not available

Data is currently unavailable.

How to read profitability and growth

This section helps investors review Purple Biotech (NASDAQ-PPBT) from an operating perspective by combining current scale, forward revenue expectations and EBITDA-related profitability measures.

Quality • Risk

Quality & Financial Risk for Purple Biotech (NASDAQ-PPBT)

Review financial health, earnings quality and balance-sheet risk through Piotroski, Beneish, Altman and cash conversion metrics.

Financial Health

Fair

Mixed or neutral financial-health read.

Piotroski Score

0

Weak quality score that deserves closer review.

Beneish M-Score

NM

Forensic accounting screen.

Altman Z-Score

-79.1

Lower score that deserves closer risk review.

FCF / Net Income

26.1%

Cash conversion quality indicator.

How to read quality and risk

This section combines quality, balance-sheet and accounting-risk indicators for Purple Biotech (NASDAQ-PPBT). Read the metrics together: no single score is a complete investment conclusion, but the combined view can highlight financial strength, earnings quality and areas that may deserve closer review.

Events • Dividends

Upcoming Events & Dividends for Purple Biotech (NASDAQ-PPBT)

Track the next earnings date, ex-dividend date, dividend payment date, dividend yield and upcoming distribution details where available.

Next Earnings Date

July 30, 2026

Days to Earnings

9

Dividend Payment Date

Not available

Ex-Dividend Date

Not available

Dividend Yield

0.0%

Income yield reference.

Upcoming Dividend

Not available

Data is currently unavailable.

Payment Type

Not available

Data is currently unavailable.

Dividend Currency

Not available

Data is currently unavailable.

Payout Ratio

Not available

Data is currently unavailable.

How to read events and dividends

This section helps investors track time-sensitive items for Purple Biotech (NASDAQ-PPBT), including the next earnings date and dividend-related milestones. These items can matter for short-term volatility, income planning and event-driven positioning.

Stock Forecast • Technical Outlook

Purple Biotech (NASDAQ-PPBT) Stock Forecast & Technical Outlook

Review Purple Biotech (NASDAQ-PPBT) across multiple technical time frames, alongside analyst recommendation data, to form a faster read on market positioning and near-term sentiment.

Technical Signals by Time Frame

Switch between time frames to review the current technical signal for the stock.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 15-minute • intraday
Strong Sell

The 15-minute technical read for Purple Biotech (NASDAQ-PPBT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: 1-hour • short-term
Strong Sell

The 1-hour technical read for Purple Biotech (NASDAQ-PPBT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: daily • daily
Strong Sell

The daily technical read for Purple Biotech (NASDAQ-PPBT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: weekly • weekly
Strong Sell

The weekly technical read for Purple Biotech (NASDAQ-PPBT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Strong Sell Sell Neutral Buy Strong Buy
Time frame: monthly • monthly
Strong Sell

The monthly technical read for Purple Biotech (NASDAQ-PPBT) is currently Strong Sell. Use it as a timing signal only, and compare it with valuation, fundamentals and upcoming events before drawing a broader view.

Analyst Consensus for Purple Biotech (NASDAQ-PPBT)

A consolidated view of buy, hold and sell recommendations based on the currently available analyst data.

Strong Sell Sell Neutral Buy Strong Buy
Consolidated analyst recommendation mix
Strong Buy

Based on the available recommendation mix, Purple Biotech (NASDAQ-PPBT) has a Strong Buy consensus, with 1 buy, 0 hold and 0 sell recommendations in the current data set.

Buy 1
Hold 0
Sell 0
FAQ • Fast Investor Answers

Purple Biotech (NASDAQ-PPBT) Stock FAQ

Quick answers about Purple Biotech (NASDAQ-PPBT) stock, including fair value, valuation rating, analyst price target, dividends, earnings dates, market capitalization, financial health and other key stock analysis metrics.

Fair Value
Not available
Data is currently unavailable
Valuation Rating
Not available
Classification is not available
Analyst Target
$30 2,073.9% Upside
Data is currently unavailable
Financial Health
Fair
Current financial-health read

A fair value estimate for Purple Biotech (NASDAQ-PPBT) is not currently available in the latest data file.

A clear undervalued or overvalued classification is not currently available in the latest data file.

The available analyst price target for Purple Biotech (NASDAQ-PPBT) is $30 2,073.9% Upside.

The current financial health read for Purple Biotech (NASDAQ-PPBT) is Fair. This should be reviewed alongside valuation, profitability, debt and cash-flow quality metrics.

The next earnings date currently listed for Purple Biotech (NASDAQ-PPBT) is July 30, 2026.

Based on the current data, dividend yield is 0.0%.

The current P/E ratio listed for Purple Biotech (NASDAQ-PPBT) is -0.2x. Use it together with growth, margins and sector comparisons rather than as a standalone valuation signal.

The current market capitalization listed for Purple Biotech is 6.118 M.

The current enterprise value listed for Purple Biotech is -408.685 K. Enterprise value can provide a broader valuation view than market capitalization alone because it also considers net debt.

The ticker symbol for Purple Biotech is NASDAQ-PPBT, and the stock is listed on NASDAQ.

Purple Biotech (NASDAQ-PPBT) is listed on NASDAQ.

The current debt-to-total-capital ratio listed for Purple Biotech is 3.0%, which helps investors evaluate the company’s financing structure and leverage profile.

The free float listed for Purple Biotech is 99.4%. Free float helps investors understand how much of the share base is available for public trading.

Similar Pharmaceuticals Stocks on NASDAQ View more

AstraZeneca PLC ADR (AZN) AstraZeneca PLC ADR (AZN)
Sanofi ADR (SNY) Sanofi ADR (SNY)
Royalty Pharma Plc (RPRX) Royalty Pharma Plc (RPRX)
Viatris Inc (VTRS) Viatris Inc (VTRS)
Jazz Pharmaceuticals PLC (JAZZ) Jazz Pharmaceuticals PLC (JAZZ)
Axsome Therapeutics Inc (AXSM) Axsome Therapeutics Inc (AXSM)
Corcept Therapeutics Incorporated (CORT) Corcept Therapeutics Incorporated (CORT)
Crinetics Pharmaceuticals Inc (CRNX) Crinetics Pharmaceuticals Inc (CRNX)
Liquidia Technologies Inc (LQDA) Liquidia Technologies Inc (LQDA)
Belite Bio Inc ADR (BLTE) Belite Bio Inc ADR (BLTE)
Ligand Pharmaceuticals Incorporated (LGND) Ligand Pharmaceuticals Incorporated (LGND)
Definium Therapeutics Inc (DFTX) Definium Therapeutics Inc (DFTX)
Amneal Pharmaceuticals Inc Class A (AMRX) Amneal Pharmaceuticals Inc Class A (AMRX)
Indivior PLC (INDV) Indivior PLC (INDV)
Edgewise Therapeutics Inc (EWTX) Edgewise Therapeutics Inc (EWTX)
Enliven Therapeutics Inc (ELVN) Enliven Therapeutics Inc (ELVN)
Alumis Inc (ALMS) Alumis Inc (ALMS)
Structure Therapeutics Inc ADR (GPCR) Structure Therapeutics Inc ADR (GPCR)
MBX Biosciences Inc (MBX) MBX Biosciences Inc (MBX)
Supernus Pharmaceuticals Inc (SUPN) Supernus Pharmaceuticals Inc (SUPN)
ATAI Beckley Inc (ATAI) ATAI Beckley Inc (ATAI)
Regencell Bioscience Holdings Ltd (RGC) Regencell Bioscience Holdings Ltd (RGC)
Tarsus Pharmaceuticals Inc (TARS) Tarsus Pharmaceuticals Inc (TARS)
Trevi Therapeutics Inc (TRVI) Trevi Therapeutics Inc (TRVI)